Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies
- 1 July 1990
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 32 (4), 245-250
- https://doi.org/10.1007/bf01741708
Abstract
Cytotoxic T lymphocytes from healthy donors can be expanded to high numbers from the peripheral blood using combinations of anti-CD3 and anti-CD28 monoclonal antibodies (mAb). We investigated whether these antibodies could also be used to induce outgrowth of tumour-infiltrating lymphocytes (TIL) from tumour tissue. In the initiation phase of TIL culture immobilized anti-CD3 antibodies together with anti-CD28 mAb and low-dose interleukin-2 induced a rapid expansion of T cells from various human tumour tissues. The cultured cells showed high levels of cytotoxic T lymphocyte activity, but low levels of lymphokine-activated killer cell activity were generated. This study shows that TIL can be efficiently expanded from tumour tissue by combinations of anti-CD3 and anti-CD28 antibodies. This protocol for cell expansion in vitro may substantially reduce the time required to reach sufficient numbers of TIL for re-infusion to the patient.Keywords
This publication has 27 references indexed in Scilit:
- Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.The Journal of Experimental Medicine, 1989
- Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibodyInternational Journal of Cancer, 1989
- Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.The Journal of Experimental Medicine, 1989
- Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation PathwayScience, 1989
- In vitro activation of lymphocytes from nonsmall cell cancer patients by interleukin 2 and anti-CD3 antibodyClinical Immunology and Immunopathology, 1989
- Proliferative and cytolytic potentials of purified human tumor-infiltrating t lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expressionInternational Journal of Cancer, 1988
- Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.The Journal of Experimental Medicine, 1988
- Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.The Journal of Experimental Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activationEuropean Journal of Immunology, 1986